Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

BD Diagnostics, Diagenode to jointly develop molecular diagnostic assays

BD Diagnostics and Belgium-based biotech company Diagenode have agreed to jointly develop seven CE-marked molecular diagnostic assays on the BD MAX System for pathogens.

The initial assays will include a respiratory panel for diagnosing respiratory infections, two panels for diagnosing virus- and parasite-based gastrointestinal infections and a panel for differentially diagnosing meningitis.

BD Diagnostics, a segment of global medical technology company BD (Becton, Dickinson and Company), plans to fully integrate these in vitro diagnostic (IVD) assays onto the BD MAX platform and ultimately assume responsibility for manufacturing and commercializing the tests globally.

BD Diagnostics – Diagnostic Systems president Tom Polen said the BD MAX System’s content-rich menu and open capability, full automation and standardized workflow will enable laboratories to consolidate and standardize a broad range of molecular tests to build programs that meet both their current and future clinical needs.